NRx Pharmaceuticals Inc. (NRXPW)
0.10
-0.00 (-3.61%)
At close: Mar 03, 2025, 9:30 AM
NRx Pharmaceuticals Income Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | 5K | 4K | 2K | 907.41K | n/a | 1.01M | n/a |
| Gross Profit | -5K | -4K | -2K | -907.41K | n/a | -1.01M | n/a |
| Operating Income | -27.59M | -44.4M | -115.8M | -51.39M | -6.26K | -1.01M | n/a |
| Interest Income | 494K | 249K | 18.00 | 56.00 | 1.21M | 1.09M | n/a |
| Pretax Income | -30.16M | -39.82M | -93.06M | -51.78M | 492.63K | 82.41K | -105.03K |
| Net Income | -30.15M | -35.23M | -71.72M | -12.35M | 408.43K | 66.1K | -105.03K |
| Selling & General & Admin | 14.21M | 27.37M | 74.94M | 11.44M | 2.77K | 1.01M | n/a |
| Research & Development | 13.37M | 17.03M | 20.26M | 10.63M | 3.5K | n/a | n/a |
| Other Expenses | n/a | -505K | -771K | -10.16M | 713.19K | 1.01M | n/a |
| Operating Expenses | 27.58M | 44.4M | 94.43M | 11.9M | 6.43K | 1.01M | n/a |
| Interest Expense | 120K | n/a | 18K | 56K | n/a | n/a | n/a |
| Selling & Marketing Expenses | -5K | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 27.59M | 44.4M | 94.43M | 11.9M | 6.43K | 1.01M | n/a |
| Income Tax | -9K | -4.58M | -21.35M | -39.43M | 84.21K | 16.31K | n/a |
| Shares Outstanding (Basic) | 7.58M | 65.77M | 46.92M | 34.27M | 508.83K | 892.5K | 903.55K |
| Shares Outstanding (Diluted) | 7.58M | 65.77M | 46.92M | 34.27M | 508.83K | 892.5K | 903.55K |
| EPS (Basic) | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| EPS (Diluted) | -3.98 | -0.54 | -1.53 | -0.36 | 0.80 | 0.07 | -0.12 |
| EBITDA | -30.02M | -39.75M | -93.04M | -51.72M | -713.19K | 82.41K | -105.04K |
| Depreciation & Amortization | 5K | 4K | 2K | 2K | 0.86 | 1.09M | 52.52K |